Kodiak Sciences to present strong KSI-101 results at major vision conferences

Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.

The presentations will center on the company’s lead dual-inhibitor candidate, KSI-101, with a specific focus on the Week 24 results from the MESI study and data from an Asian tertiary-care cohort.

Preliminary data disclosed ahead of the conferences highlights the potent anatomical and functional impact of KSI-101.

In an Asian tertiary-care cohort, 58% of patients achieved visual gains of 15 letters or more on the Best Corrected Visual Acuity (BCVA) scale.

By Week 24, the cohort showed a mean improvement of +17.8 letters, suggesting a significant therapeutic benefit in complex patient populations.

The anatomical results were equally robust, demonstrating the rapid onset of action of the drug.

Central Subfield Thickness (CST) was reduced to less than 325 µm following a single injection.

Furthermore, data from the APEX study indicated that more than 90% of patients achieved complete resolution of intraretinal fluid (IRF) and subretinal fluid (SRF) by Week 8 of treatment.

These results are particularly significant for Kodiak as it seeks to differentiate KSI-101 in a competitive anti-VEGF market.

By simultaneously targeting multiple pathways involved in retinal vascular diseases, the compound aims to provide deeper and more durable responses than current standards of care.

The upcoming presentations are expected to provide further clarity on the safety profile and long-term durability of these responses.